Managing Partner
Maia Venture Partners, USA

Keting Chu joined Apple Tree Partners in 2016 as a Venture Partner. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture philanthropy.
Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment of Celator, Stemline, Constellation, Affimed, arGen-X, Kite Pharma, Kiadis, OncoPepe, Valor and a number of projects within academic institutions. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. Prior to co-founding DigitAB, Keting was the Co-Founder and CEO of BioCubed Corporation, Vice President of Biology and Head of R&D at Five Prime Therapeutics during its founding stage and the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.
Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, PhD in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.

Upcomming summits